RACHEL MULLINS: Open Payments
NPI 1043442064 · TOLEDO, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$556 in 25 payments from 10 companies in 2025. Trend: 2023 $500 · 2024 $612 · 2025 $556
Food & beverage: $556
| Company | Payments | Amount |
|---|---|---|
| Kerecis Limited | 8 | $237 |
| ABBVIE INC. | 5 | $106 |
| Novo Nordisk Inc | 4 | $70 |
| MIMEDX Group, Inc. | 2 | $36 |
| Lilly USA, LLC | 1 | $22 |
| SHIELD THERAPEUTICS INC | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| Solventum Corporation | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: Kerecis SurgiClose, VRAYLAR, Ozempic, DALVANCE, MOUNJARO, ACCRUFER, CAMZYOS, XIFAXAN.
Industry payments across OH — which companies pay providers there.
